Skip to main content

Typhoid Fever

11
Pipeline Programs
10
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
5
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
8100%
+ 12 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

EuBiologics
EuBiologicsKorea - Seoul
2 programs
1
1
EuTCVPhase 2/31 trial
EuTCVPhase 11 trial
Active Trials
NCT03956524Completed75Est. Aug 2019
NCT04830371Completed444Est. Aug 2021
Sandoz
SandozAustria - Kundl
5 programs
1
4
NVGH Vi-CRM197Phase 21 trial
NVGH Vi-CRM197 12.5 mcgPhase 21 trial
Vi-CRM197 vaccinePhase 2Vaccine1 trial
Vi-CRM197 vaccinePhase 2Vaccine1 trial
TypherixPhase 11 trial
Active Trials
NCT01123941Completed50Est. Nov 2010
NCT01438996Completed51Est. Dec 2011
NCT01193907Completed88Est. Nov 2010
+2 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
Vi-rEPA conjugate vaccine for typhoid feverPhase 2Vaccine1 trial
BB IND 6989Phase 11 trial
Active Trials
NCT00277147Completed25Est. Sep 2008
NCT00342628Completed301Est. Jan 2011
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
TYP04A Low Dose without Alum investigational vaccinePhase 1Vaccine
Biological E.
Biological E.India - Hyderabad
1 program
1
TYP04A Low Dose without Alum investigational vaccinePhase 1Vaccine
Novartis
NovartisBASEL, Switzerland
5 programs
TypherixPHASE_1
NVGH Vi-CRM197PHASE_2
NVGH Vi-CRM197 12.5 mcgPHASE_2
Vi-CRM197 vaccinePHASE_2Vaccine
Vi-CRM197 vaccinePHASE_2Vaccine
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
VivotifN/A1 trial
Active Trials
NCT02391909Completed855Est. Feb 2017
Emergent BioSolutions
1 program
VivotifN/A
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
VivotifN/A
GSK
GSKLONDON, United Kingdom
1 program
TYP04A Low Dose without Alum investigational vaccinePHASE_1Vaccine1 trial
Active Trials
NCT05613205Completed97Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EuBiologicsEuTCV
SandozNVGH Vi-CRM197
SandozVi-CRM197 vaccine
SandozVi-CRM197 vaccine
SandozNVGH Vi-CRM197 12.5 mcg
Human BioSciencesVi-rEPA conjugate vaccine for typhoid fever
GSKTYP04A Low Dose without Alum investigational vaccine
EuBiologicsEuTCV
SandozTypherix
Human BioSciencesBB IND 6989
Bavarian NordicVivotif

Clinical Trials (11)

Total enrollment: 2,306 patients across 11 trials

NCT04830371EuBiologicsEuTCV

Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Start: Sep 2020Est. completion: Aug 2021444 patients
Phase 2/3Completed
NCT01438996SandozNVGH Vi-CRM197

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Start: Oct 2011Est. completion: Dec 201151 patients
Phase 2Completed
NCT01437267SandozVi-CRM197 vaccine

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Start: Oct 2011Est. completion: Aug 2012120 patients
Phase 2Completed
NCT01229176SandozVi-CRM197 vaccine

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

Start: Mar 2011Est. completion: Jun 2012200 patients
Phase 2Completed
NCT01193907SandozNVGH Vi-CRM197 12.5 mcg

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Start: Oct 2010Est. completion: Nov 201088 patients
Phase 2Completed
NCT00342628Human BioSciencesVi-rEPA conjugate vaccine for typhoid fever

Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants

Start: Jul 2006Est. completion: Jan 2011301 patients
Phase 2Completed
NCT05613205GSKTYP04A Low Dose without Alum investigational vaccine

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Start: Nov 2022Est. completion: Apr 202497 patients
Phase 1Completed
NCT03956524EuBiologicsEuTCV

Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

Start: Mar 2019Est. completion: Aug 201975 patients
Phase 1Completed
NCT01123941SandozTypherix

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Start: May 2010Est. completion: Nov 201050 patients
Phase 1Completed
NCT00277147Human BioSciencesBB IND 6989

Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine

Start: Jan 2006Est. completion: Sep 200825 patients
Phase 1Completed
NCT02391909Bavarian NordicVivotif

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Start: Aug 2015Est. completion: Feb 2017855 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.